Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
2013 1
2015 1
2016 2
2017 2
2018 1
2021 2
2022 2
2023 1
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Tarazi J, Sridharan S, Sugg J, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Zohren F, Shore ND; EMBARK Study. Freedland SJ, et al. N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974. N Engl J Med. 2023. PMID: 37851874 Clinical Trial.
Estetrol Inhibits the Prostate Cancer Tumor Stimulators FSH and IGF-1.
Coelingh Bennink HJT, Roos EPM, van Moorselaar RJA, van Melick HHE, Somford DM, Roeleveld TA, de Haan TD, Reisman Y, Schultz IJ, Krijgh J, Debruyne FMJ. Coelingh Bennink HJT, et al. Among authors: roos epm. J Clin Med. 2024 Oct 8;13(19):5996. doi: 10.3390/jcm13195996. J Clin Med. 2024. PMID: 39408055 Free PMC article.
Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review.
Coelingh Bennink HJT, Krijgh J, Egberts JFM, Slootweg M, van Melick HHE, Roos EPM, Somford DM, Zimmerman Y, Schultz IJ, Clarke NW, van Moorselaar RJA, Debruyne FMJ. Coelingh Bennink HJT, et al. Among authors: roos epm. Endocr Connect. 2022 Nov 18;11(12):e220182. doi: 10.1530/EC-22-0182. Print 2022 Dec 1. Endocr Connect. 2022. PMID: 36283120 Free PMC article. Review.
The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
Bancroft EK, Page EC, Brook MN, Pope J, Thomas S, Myhill K, Helfand BT, Talaty P, Ong KR, Douglas E, Cook J, Rosario DJ, Salinas M, Buys SS, Anson J, Davidson R, Longmuir M, Side L, Eccles DM, Tischkowitz M, Taylor A, Cruellas M, Ballestero EP, Cleaver R, Varughese M, Barwell J, LeButt M, Greenhalgh L, Hart R, Azzabi A, Jobson I, Cogley L, Evans DG, Rothwell J, Taylor N, Hogben M, Saya S; IMPACT Study Steering Committee; IMPACT Collaborators; Eeles RA, Aaronson NK. Bancroft EK, et al. BJU Int. 2024 Sep;134(3):484-500. doi: 10.1111/bju.16432. Epub 2024 Jun 5. BJU Int. 2024. PMID: 38839570 Free article.
Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study.
Zimmerman Y, Frydenberg M, van Poppel H, van Moorselaar RJA, Roos EPM, Somford DM, Roeleveld TA, de Haan TD, van Melick HHE, Reisman Y, Krijgh J, Debruyne FMJ, Coelingh Bennink HJT. Zimmerman Y, et al. Among authors: roos epm. Eur Urol Open Sci. 2022 Oct 3;45:59-67. doi: 10.1016/j.euros.2022.09.006. eCollection 2022 Nov. Eur Urol Open Sci. 2022. PMID: 36353657 Free PMC article.
Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi).
Coelingh Bennink HJT, van Moorselaar JA, Crawford ED, Roos EPM, Somford DM, Roeleveld TA, de Haan TD, van Melick HHE, Reisman Y, Zimmerman Y, van Osta G, Krijgh J, Shore ND, Saad F, Schally AV, Debruyne FMJ. Coelingh Bennink HJT, et al. Among authors: roos epm. Eur Urol Open Sci. 2021 May 6;28:52-61. doi: 10.1016/j.euros.2021.04.005. eCollection 2021 Jun. Eur Urol Open Sci. 2021. PMID: 34337526 Free PMC article.
A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
Roehrborn CG, Manyak MJ, Palacios-Moreno JM, Wilson TH, Roos EPM, Santos JC, Karanastasis D, Plastino J, Giuliano F, Rosen RC. Roehrborn CG, et al. Among authors: roos epm. BJU Int. 2018 Apr;121(4):647-658. doi: 10.1111/bju.14057. Epub 2017 Nov 16. BJU Int. 2018. PMID: 29044968 Clinical Trial.
Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.
Roehrborn CG, Oyarzabal Perez I, Roos EP, Calomfirescu N, Brotherton B, Wang F, Palacios JM, Vasylyev A, Manyak MJ. Roehrborn CG, et al. Among authors: roos ep. BJU Int. 2015 Sep;116(3):450-9. doi: 10.1111/bju.13033. Epub 2015 Jan 29. BJU Int. 2015. PMID: 25565364 Clinical Trial.
The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate-a long-term follow-up comparison and quality of life analysis.
Dijkstra S, Witjes WP, Roos EP, Vijverberg PL, Geboers AD, Bruins JL, Smits GA, Vergunst H, Mulders PF. Dijkstra S, et al. Among authors: roos ep. Springerplus. 2016 May 17;5:653. doi: 10.1186/s40064-016-2280-8. eCollection 2016. Springerplus. 2016. PMID: 27330919 Free PMC article.
13 results